Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Light Shed on Differential Effectiveness of Aminoglycosides Against Parasitic Protozoa

By BiotechDaily International staff writers
Posted on 20 Aug 2013
Image: Crystal structure visualization of [geneticin (G418)] – [leishmanial A-site rRNA] complex (Photo courtesy of Prof. Baasov and Prof. Adir of Technion – Israel Institute of Technology – via PNAS).
Image: Crystal structure visualization of [geneticin (G418)] – [leishmanial A-site rRNA] complex (Photo courtesy of Prof. Baasov and Prof. Adir of Technion – Israel Institute of Technology – via PNAS).
Previously unknown factors have now been identified as important in the differential effectiveness of various aminoglycosides in being used or developed to treat leishmaniasis, with similar implications for treating human diseases caused by other parasitic protozoa.

Aminoglycosides (AGs) are well known as highly potent, broad-spectrum antibiotics and have been extensively investigated as such. The homologous site of AG action (known to be or putatively the decoding “ribosomal A site”) in eukaryotes highlights the potential of some AGs for treating relevant human genetic disorders as well as parasitic infections caused by lower eukaryotes, such as in leishmaniasis, trypanosomiasis, giardiasis, and amoebiasis. However, too few studies have been done to characterize AG activity in eukaryotes.

The new findings, from the laboratories of Prof. Timor Baasov and Prof. Noam Adir of the Technion – Israel Institute of Technology (Haifa, Israel), Prof. Charles Jaffe of the Hebrew University (Jerusalem, Israel), and Assistant Prof. Jiro Kondo of Sophia University (Tokyo, Japan), examined the molecular mechanism as well as inhibition activity of AGs in Leishmania as a model organism for eukaryotes in general and for parasitic protozoa in particular. Some AGs have recently been clinically approved and are currently used worldwide for the treatment of leishmaniasis, such as geneticin and, particularly, paromomycin, to which parasite resistance is also on the rise.

Five AGs were chosen for comparison in terms of the anti-leishmanial activity part of the study, performed with a growth-inhibition assay (LC50) on Leishmania promastigotes in culture: paromomycin and neomycin B of one class, gentamicin and geneticin of another class, and apramycin of another. Two Leishmania species were used for these susceptibility assays – L. major, causing cutaneous disease, and L. donovani, causing fatal visceral disease if not diagnosed and treated in time. Two AGs were chosen for comparison in terms of the structural mechanism part of the study, performed with X-ray crystallography based modeling: geneticin (also known as G418) due to its high potency for the treatment of leishmaniasis, and apramycin due to its lack of anti-leishmanial activity yet being a strong binder of the leishmanial ribosome. The crystal structures were made of the AGs bound to rRNA duplex constructs mimicking their putative leishmanial binding site.

Analyses of the combined structural and physiological data provide important new insight into the anti-leishmanial activities, or lack thereof, of certain AG structural derivatives. The physiological, parasite susceptibility data indicate, for example, that geneticin is more potent than paromomycin, which is more potent than gentamicin and neomycin. This is in agreement with previous work reporting, for example, lower treatment potency of neomycin compared with paromomycin. Notably, the AGs were more effective against L. major growth than L. donovani, which might be due to species differences that affect AG permeability. Apramycin did not appear here to inhibit growth. The structural data indicate, for example among several, that ability of an AG (here, geneticin) to induce the ON-state conformation is highly important for its observed potency as an anti-Leishmania agent, thus implying the significance of translatory miscoding events in the killing mechanism.

The study was published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) online, ahead of print, July 29, 2013.

Related Links:
Technion – Israel Institute of Technology
Hebrew University of Jerusalem
Sophia University


comments powered by Disqus

Channels

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.